The United States of America, As Represented by the Secretary, Department of Health and Human Services

Institute for Research in Biomedicine

Columbia University

The Pirbright Institute

Baoshan Zhang

Peter D Kwong

Yongping Yang

Ivelin Georgiev

Gwo-Yu Chuang

Guillaume Stewart-Jones

Tongqing Zhou

Michael Gordon Joyce

John R Mascola

Wing-Pui Kong

Aliaksandr Druz

Marie Pancera

Li Ou

Antonio Lanzavecchia

Davide Corti

Barney S Graham

Mark Connors

Man Chen

Gilad Ofek

Mallika Sastry

Yaroslav Tsybovsky

Gary J Nabel

John Mascola

Jason Gorman

Kai Xu

Jiang Zhu

Rebecca S Rudicell

Cinque Soto

Cheng Cheng

Jason Scott McLellan

Young Do Kwon

Paul Thomas

Peter L Collins

Ursula J Buchholz

Jeffrey C Boyington

Ulrich Baxa

Lei Chen

Masaru Kanekiyo

Zhi-yong Yang

Wei Shi

Xueling Wu

Jinghe Huang

Joseph Van Galen

Leo Laub

Sanjay Srivatsan

Wing-pui Kong

Rita Chen

Priyamvada Acharya

Emily Rundlet

Richard Schwartz

Lawrence Shapiro

Sijy O'Dell

Kevin Liu

Rui Kong

Krisha McKee

Amarendra Pegu

Robert Bailer

Mark Louder

Lisa Kueltzo

Tatyana Gindin

Mangaiarkarasi Asokan

Jonathan Cooper

Kevin Carlton

Michael Bender

Rebecca M Lynch

Geraldine Taylor

Cara W Chao

Yiran Wang

Jason S Mclellan

Ivelin Stefanov Georgiev

Rebecca Lynch

Leo B Laub

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 ENV fusion peptide immunogens and their use

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Recombinant metapneumovirus f proteins and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Embodiments of immunogenic conjugates including the HIV-1 Env fusion peptide and methods of their use and production are disclosed. In several embodiments, the immunogenic conjugates can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Recombinant metapneumovirus F proteins and their use

HIV-1 Env fusion peptide immunogens and their use

Neutralizing antibodies to HIV-1 GP41 and their use

Substitutions-modified prefusion RSV F proteins and their use

Growing community of inventors

Bethesda, MD, United States of America

Baoshan Zhang